Direct Proinflammatory Effect of C-reactive Protein on Human Monocytes Isolated from Patients with Acute Coronary Syndrome and Statins Intervention
王海蓉,黄从新,江洪,李建军,许家俐,朱刚艳,杨波,蒋学俊,李庚山
DOI: https://doi.org/10.3321/j.issn:1001-1978.2004.11.023
2004-01-01
Abstract:Aim The accumulating evidence suggests that C- reactive protein (CRP) may have direct inflammatory effects on the vascular wall and that statin therapy may have important non-lipid anti-inflammatory effects confirmed by decreasing serum inflammatory markers,such as CRP. However, the effect of pravastatin,fluvastatin and simvastatin on interleukin-6 (IL-6) release in cultured human monocytes from patients with acute coronary syndrome(ACS) was not investigated. Methods Monocytes were isolated from blood of patients with ACS and healthy volunteers by the Ficoll density gradient and stimulated by CRP (20 mg·L -1)for 24 h. Also 1×10 -6,2.5×10 -6,5×10 -6,7.5×10 -6,1×10 -5 mol·L -1 pravastatin, fluvastatin and simvastatin was coincubated with cells in the presence of CRP. Measurements of IL-6 were performed from supernatants of cultured medium in duplicate, using a commercial assay kit. Results ① CRP induced the release of IL-6, with significantly elevated levels in cultured supernatants in ACS group, SAP group and healthy group compared with their negative control respectively . A greater than several fold increase of IL-6 induced by CRP was observed in ACS group than other group s. ② Pravastatin,fluvastatin and simvastatin inhibited significantly the produ ction of IL-6 in monocytes stimulated by CRP in dose-dependent manner, a greater decrease was observed in pravastatin and fluvastatin than simvastatin (P0.05 ). Conclusion CRP could induce more IL-6 release in human monocyte from patients with ACS than from healthy volunteer.This may contribute to the mechanism of coronary artery disease in addition to being an incidental product of various types of systemic inflammation. Pravastatin and fluvastatin could inhibit this response in a dose-dependent manner in ACS group better than simvastatin, which may provide a new insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of pravastatin and fluvastatin.